---
title: "Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) in pneumococcal disease prevention in adults: Clinical trials questions"
description: "Clinical trials questions on Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) in pneumococcal disease prevention in adults, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Interpreting study results and Study results. Questions: How was Prevnar 20 effectiveness in adults established? Prevnar 20 vs Prevnar 13 and PPSV23: how did immune responses compare in adults 60+? How was Prevnar 20 effectiveness inferred in adults 18 to 59? What immune responses did Prevnar 20 produce in previously vaccinated adults 65+? 1 further question follow. 5 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults/clinical-trials"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) in pneumococcal disease prevention in adults: Clinical trials questions

Manufacturer: Wyeth Pharmaceutical Division of Wyeth Holdings LLC  
Prescribing information: [Prevnar 20](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428)

Clinical trials questions that apply to every indication of Prevnar 20 are on [Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine), all indications: Clinical trials](https://www.evicenter.com/medical-information/prevnar-20/clinical-trials).

## Interpreting study results

<a id="prevnar20-effectiveness-basis"></a>

### How was Prevnar 20 effectiveness in adults established?

> “Prevnar 20 effectiveness in adults against invasive pneumococcal disease caused by the 20 vaccine serotypes and against pneumonia caused by the 13 serotypes in Prevnar 13 was demonstrated based on comparative immunogenicity to US-licensed pneumococcal vaccines (Prevnar 13 and PPSV23).”

Source: [PREVNAR 20: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428#:~:text=Prevnar%2020%20effectiveness%20in%20adults,vaccines%20%28Prevnar%2013%20and%20PPSV23%29.)

> “An opsonic antibody titer or serotype-specific IgG concentration that is predictive of protection against invasive pneumococcal disease or pneumococcal pneumonia has not been established.”

Source: [PREVNAR 20: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428#:~:text=An%20opsonic%20antibody%20titer%20or,pneumonia%20has%20not%20been%20established.)

## Study results

<a id="prevnar20-study1-immune-response"></a>

### Prevnar 20 vs Prevnar 13 and PPSV23: how did immune responses compare in adults 60+?

Applies to: Pneumococcal vaccine-naive adults 60 years of age and older (Study 1)

> “Participants 60 years of age and older were randomly assigned (1:1 ratio) to Prevnar 20 followed 1 month later with saline placebo or to Prevnar 13 followed 1 month later with PPSV23.”

Source: [PREVNAR 20: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428#:~:text=Participants%2060%20years%20of%20age%20and%20older%20were,1%20month%20later%20with%20PPSV23.)

> “Serotype-specific OPA GMTs were measured before the first vaccination and 1 month after each vaccination. Noninferiority of immune responses, OPA GMTs 1 month after vaccination, with Prevnar 20 to a control vaccine for a serotype was declared if the lower bound of the 2 sided 95% CI for the GMT ratio (Prevnar 20/Prevnar 13; Prevnar 20/PPSV23) for that serotype was greater than 0.5.”

Source: [PREVNAR 20: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428#:~:text=Serotype%2Dspecific%20OPA%20GMTs%20were%20measured,serotype%20was%20greater%20than%200.5.)

> “In individuals 60 years of age and older, immune responses to all 13 matched serotypes elicited by Prevnar 20 were noninferior to the immune responses to the serotypes elicited by Prevnar 13 one month after vaccination. Immune responses to 6 out of the 7 additional serotypes induced by Prevnar 20 were noninferior to the immune responses to these same serotypes induced by PPSV23 one month after vaccination. The response to serotype 8 missed the prespecified statistical noninferiority criterion by a small margin (the lower bound of the 2-sided 95% CI for the GMT ratio being 0.49 versus >0.50) (Table 13).”

Source: [PREVNAR 20: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428#:~:text=In%20individuals%2060%20years%20of%20age%20and%20older%2C%20immune,0.49%20versus%20%3E0.50%29%20%28Table%2013%29.)

> “In supportive analyses, 77.8% of participants in the Prevnar 20 group achieved a ≥4-fold rise in serotype 8 OPA titers from before vaccination to 1 month post-vaccination.”

Source: [PREVNAR 20: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428#:~:text=In%20supportive%20analyses%2C%2077.8%25%20of,vaccination%20to%201%20month%20post%2Dvaccination.)

Note: Study 1 compared Prevnar 20 with Prevnar 13 for the 13 shared serotypes and with PPSV23 (23-valent pneumococcal polysaccharide vaccine) for the 7 additional serotypes. The label reports each serotype's GMTs and GMT ratio in Table 13.

<a id="prevnar20-study1-adults-18-59"></a>

### How was Prevnar 20 effectiveness inferred in adults 18 to 59?

Applies to: Pneumococcal vaccine-naive adults 18 through 59 years of age (Study 1 immunobridging)

> “In Study 1 (described above), the effectiveness of Prevnar 20 in individuals 50 through 59 years of age and in individuals 18 through 49 years of age was inferred following comparison of the immune response to each of the 20 vaccine serotypes in each of these age groups to the corresponding serotype-specific immune responses in individuals 60 through 64 years of age following Prevnar 20 (immunobridging).”

Source: [PREVNAR 20: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428#:~:text=In%20Study%201%20%28described%20above%29%2C,age%20following%20Prevnar%2020%20%28immunobridging%29.)

> “Prevnar 20 elicited serotype-specific immune responses to each of the 20 vaccine serotypes in both of the younger age groups that were within 2-fold of the corresponding serotype-specific responses in individuals 60 through 64 years of age, when measured 1 month after vaccination (Table 14).”

Source: [PREVNAR 20: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428#:~:text=Prevnar%2020%20elicited%20serotype%2Dspecific%20immune,month%20after%20vaccination%20%28Table%2014%29.)

<a id="prevnar20-study6-previously-vaccinated"></a>

### What immune responses did Prevnar 20 produce in previously vaccinated adults 65+?

Applies to: Adults 65 years of age and older previously vaccinated with a pneumococcal vaccine (Study 6)

> “A randomized, open-label clinical trial (Study 6) described immune responses to Prevnar 20 in individuals 65 years of age and older previously vaccinated with PPSV23 (≥1 to ≤5 years prior to enrollment), previously vaccinated with Prevnar 13 (≥6 months prior to enrollment), or previously vaccinated with Prevnar 13 followed by PPSV23 (with PPSV23 vaccination ≥1 year prior to enrollment). Participants in this clinical trial previously vaccinated with Prevnar 13 (Prevnar 13 only or followed by PPSV23) were enrolled at sites in the United States and participants previously vaccinated with PPSV23 only were also enrolled from Swedish sites (35.5% in that category). Immune responses elicited by Prevnar 20 were measured by an OPA assay.”

Source: [PREVNAR 20: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428#:~:text=A%20randomized%2C%20open%2Dlabel%20clinical%20trial,measured%20by%20an%20OPA%20assay.)

> “OPA GMTs in participants who received PPSV23 1 to 5 years prior to Prevnar 20 were diminished compared to OPA GMTs in participants who received Prevnar 13 at least 6 months previously and compared to OPA GMTs in participants who received Prevnar 13 followed by PPSV23, with the last PPSV23 dose given at least 1 year prior to Prevnar 20.”

Source: [PREVNAR 20: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428#:~:text=OPA%20GMTs%20in%20participants%20who,year%20prior%20to%20Prevnar%2020.)

> “There is no noninferiority analysis of Study 6.”

Source: [PREVNAR 20: Study 6 Design, captured 2026-11-13](https://prevnar20adult.pfizerpro.com/clinical-studies/study-6-design#:~:text=There%20is%20no%20noninferiority%20analysis%20of%20Study%206.)

<a id="prevnar20-prevnar-13-capita"></a>

### What did the Prevnar 13 CAPiTA trial show in adults 65 and older?

Applies to: Prevnar 13 (13-valent predecessor vaccine) in adults 65 years of age and older (CAPiTA); cited by the label as relevant to Prevnar 20

> “Efficacy and effectiveness of Prevnar and Prevnar 13 are relevant to Prevnar 20, since Prevnar, Prevnar 13 and Prevnar 20 are manufactured similarly. In addition, Prevnar and Prevnar 20 contain 7 of the same polysaccharide conjugates and Prevnar 13 and Prevnar 20 contain 13 of the same polysaccharide conjugates.”

Source: [PREVNAR 20: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428#:~:text=Efficacy%20and%20effectiveness%20of%20Prevnar,of%20the%20same%20polysaccharide%20conjugates.)

> “The efficacy of Prevnar 13 against vaccine-type (VT) pneumococcal community-acquired pneumonia (CAP) and IPD was assessed in a randomized, double-blind, placebo-controlled study (Community-Acquired Pneumonia Immunization Trial in Adults [CAPiTA]) conducted over ~4 years in the Netherlands. A total of 84,496 participants 65 years of age and older received a single dose of either Prevnar 13 or placebo in a 1:1 randomization; 42,240 participants were vaccinated with Prevnar 13 and 42,256 participants were vaccinated with placebo. Chronic medical conditions (asthma, diabetes, heart, liver, and/or lung diseases) were reported in 42.3% of study participants at baseline.”

Source: [PREVNAR 20: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428#:~:text=The%20efficacy%20of%20Prevnar%2013,of%20study%20participants%20at%20baseline.)

> “The primary objective was to demonstrate the efficacy of Prevnar 13 in the prevention of a first episode of confirmed VT-CAP (defined as presence of ≥2 specified clinical criteria, chest X-ray consistent with CAP as determined by a central committee of radiologists, and positive VT-specific urinary antigen detection assay [UAD] or isolation of VT S. pneumoniae from blood or other sterile site). The secondary objectives were to demonstrate the efficacy of Prevnar 13 in the prevention of a first episode of 1) confirmed nonbacteremic/noninvasive (NB/NI) VT-CAP (an episode of VT-CAP for which the blood culture result and any other sterile site culture results were negative for S. pneumoniae) and 2) VT-IPD (the presence of S. pneumoniae in a sterile site).”

Source: [PREVNAR 20: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428#:~:text=The%20primary%20objective%20was%20to,pneumoniae%20in%20a%20sterile%20site%29.)

> “84,496 immunocompetent adults aged 65 or older”

Source: [PREVNAR 20: CAPiTA Clinical Study, captured 2026-11-13](https://prevnar20adult.pfizerpro.com/clinical-studies/capita#:~:text=84%2C496%20immunocompetent%20adults%20aged%2065%20or%20older)

> “The median duration of follow-up per participant was 3.93 years. Prevnar 13 demonstrated statistically significant vaccine efficacy (VE) in preventing first episodes of VT pneumococcal CAP, NB/NI VT pneumococcal CAP, and VT-IPD (see Table 8).”

Source: [PREVNAR 20: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428#:~:text=The%20median%20duration%20of%20follow%2Dup,and%20VT%2DIPD%20%28see%20Table%208%29.)

> “Table 8. Vaccine Efficacy for the Primary and Secondary Efficacy Endpoints – Per-Protocol Population
> Abbreviations: CAP = community-acquired pneumonia; CI = confidence interval; NB/NI = nonbacteremic/noninvasive; IPD = invasive pneumococcal disease; VE = vaccine efficacy; VT = vaccine-type.
>
>
> Vaccine Group
>
>
>
>
> Prevnar 13
>
>
>
> Placebo
>
>
>
>
> N=42,240
>
>
>
> N=42,256
>
>
>
>
> Efficacy Endpoint
>
>
>
> Total Number of Episodes
>
>
>
> n
>
>
>
> N
>
>
>
> VE (%)
>
>
>
> (95.2% CI)
>
>
>
>
> Primary endpoint:
> First case of confirmed VT pneumococcal CAP
>
>
>
> 139
>
>
>
> 49
>
>
>
> 90
>
>
>
> 45.6
>
>
>
> (21.8, 62.5)
>
>
>
>
> Secondary endpoint:
> First episode of confirmed NB/NI VT pneumococcal CAP
>
>
>
> 93
>
>
>
> 33
>
>
>
> 60
>
>
>
> 45
>
>
>
> (14.2, 65.3)
>
>
>
>
> Secondary endpoint:
> First episode of VT-IPD
>
>
>
> 35
>
>
>
> 7
>
>
>
> 28
>
>
>
> 75
>
>
>
> (41.1, 90.9)”

Source: [PREVNAR 20: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428#:~:text=Table%208.%20Vaccine%20Efficacy%20for,%2841.1%2C%2090.9%29)

> “Prevnar 13 will only help protect against the 13 S. pneumoniae serotypes in the vaccine.”

Source: [PREVNAR 20: CAPiTA Clinical Study, captured 2026-11-13](https://prevnar20adult.pfizerpro.com/clinical-studies/capita#:~:text=Prevnar%2013%20will%20only%20help,pneumoniae%20serotypes%20in%20the%20vaccine.)

Note: CAPiTA tested Prevnar 13, the 13-valent predecessor vaccine. In Table 8, the episode columns are the total, Prevnar 13 (n), and placebo (N), followed by vaccine efficacy (VE) with its 95.2% CI.

## Related pages
- [Medical information: Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine): Pneumococcal disease prevention in adults](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults)
- [Indication](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults/indication)
- [Safety](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults/safety)
- [Specific populations](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults/guidelines)
